National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 65180-65181 [2023-20438]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
65180
Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices
9. Japanese Patent No. 6742991 issued
August 19, 2020, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–JP–
09];
10. Korean Patent No. 10–2445667
issued September 16, 2022, entitled
‘‘Anti-Human Papillomavirus 16 E7 T
Cell Receptors’’ [HHS Reference No. E–
176–2014–0–KR–10];
11. Mexican Patent No. 375379 issued
September 25, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–MX–11];
12. Saudi Arabian Patent No. 7456
issued January 5, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–SA–12];
13. United States Patent No.
10,174,098 issued January 8, 2019,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–US–13];
14. Hong Kong Patent No. HK1236203
issued January 8, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–HK–14];
15. United States Patent No.
10,870,687 issued December 22, 2020,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–US–15];
16. European Patent Application No.
19217074.4 filed December 17, 2019,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–EP–16];
17. Australian Patent No. 2019283892
issued May 13, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–AU–17];
18. Japanese Patent No. 6997267
issued December 20, 2021, entitled
‘‘Anti-Human Papillomavirus 16 E7 T
Cell Receptors’’ [HHS Reference No. E–
176–2014–0–JP–53];
19. Saudi Arabian Patent Application
No. 520412601 filed August 10, 2020,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–SA–54];
20. Hong Kong Patent Application No.
42020020661.3 filed November 24,
2020, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–
HK–55];
21. Mexican Patent Application No.
MX/a/2020/010035 filed September 24,
2020, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–
MX–56];
22. United States Patent No.
11,434,272 issued September 6, 2020,
VerDate Sep<11>2014
17:11 Sep 20, 2023
Jkt 259001
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–US–57];
23. Australian Patent No. 2021202227
issued February 23, 2023, entitled
‘‘Anti-Human Papillomavirus 16 E7 T
Cell Receptors’’ [HHS Reference No. E–
176–2014–0–AU–58];
24. Chinese Patent Application No.
20210399056.9 filed April 14, 2021,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–CN–59];
25. Israeli Patent No. 282518 issued
July 2, 2022, entitled ‘‘Anti-Human
Papillomavirus 16 E7 T Cell Receptors’’
[HHS Reference No. E–176–2014–0–IL–
60];
26. Hong Kong Patent Application No.
42022046605.6 filed January 19, 2022,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–HK–62];
27. Japanese Patent No. 7291196
issued June 6, 2023, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell
Receptors’’ [HHS Reference No. E–176–
2014–0–JP–63];
28. Israeli Patent Application No.
290655 filed February 16, 2022, entitled
‘‘Anti-Human Papillomavirus 16 E7 T
Cell Receptors’’ [HHS Reference No. E–
176–2014–0–IL–64];
29. United States Patent Application
No. 17/816,496 filed August 1, 2022,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–US–65];
30. Korean Patent Application No.
2022–7032043 filed September 15, 2022,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–KR–66];
31. Australian Patent Application No.
2023200608 filed February 6, 2023,
entitled ‘‘Anti-Human Papillomavirus
16 E7 T Cell Receptors’’ [HHS Reference
No. E–176–2014–0–AU–01]; and
32. Japanese Patent Application No.
2023–091878 filed June 2, 2023, entitled
‘‘Anti-Human Papillomavirus 16 E7 T
Cell Receptors’’ [HHS Reference No. E–
176–2014–0–JP–01].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the
following:
‘‘Development, manufacture and
commercialization of autologous T cell
therapy products that are genetically
engineered to have stable expression of
a T cell receptor (TCR) targeting human
papillomavirus (‘‘HPV’’)–16 E7, as
claimed in the Licensed Patent Rights,
for the treatment of HPV-associated
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
cancers and premalignant conditions in
humans.’’
The E–176–2014 patent family is
primarily directed to an isolated TCR
reactive to HPV 16 E7 antigen in the
context of HLA–A*02. HPV describes a
group of human viruses known to cause
malignancy. Of the group, HPV–16 is
the most prevalent strain.
Approximately 90% of adults are
estimated to have been exposed at some
point in their lifetime. HPV drives
transformation of infected cells through
the expression of certain oncoproteins,
chiefly E5, E6 and E7. The latter two are
constitutively expressed in malignant
cells and are necessary to maintain a
transformed state, rendering them useful
therapeutic targets.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: September 18, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2023–20487 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
E:\FR\FM\21SEN1.SGM
21SEN1
Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Review of
Institutional Training Grants (T32) in
Digestive Diseases and Nutrition.
Date: October 17, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Tori Stone, Ph.D.,
Scientific Review Officer, NIDDK/Scientific
Review Branch, National Institutes of Health,
6707 Democracy Blvd., Bethesda, MD 20892,
(301) 827–0994, tori.stone@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: September 15, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20438 Filed 9–20–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
ddrumheller on DSK120RN23PROD with NOTICES1
Dated: September 15, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, National Institute of
Neurological Disorders and Stroke.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), title 5 U.S.C., as amended for
the review, discussion, and evaluation
of individual intramural programs and
projects conducted by the National
Institute of Neurological Disorders and
Stroke, including consideration of
personnel qualifications and
17:11 Sep 20, 2023
Name of Committee: Board of Scientific
Counselors, National Institute of
Neurological Disorders and Stroke.
Date: October 17, 2023.
Time: 2:00 p.m. to 5:30 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: Porter Neuroscience Research
Center, Building 35A, 35 Convent Drive,
Bethesda, MD 20892 (Virtual Meeting).
Date: October 23–24, 2023.
Time: October 23, 2023, 8:30 a.m. to 9:00
p.m.; October 24, 2023, 9:00 a.m. to 12:30
p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: The Bethesdan Hotel, 8120
Wisconsin Avenue, Bethesda, Maryland
20814 (Hybrid Meeting).
Contact Person: Jeffrey S. Diamond, Ph.D.,
Scientific Director, c/o Caren Collins,
National Institute of Neurological Disorders
and Stroke, NIH, Building 35, Room GF–149,
Bethesda, MD 20892, 301–435–1896,
diamondj@ninds.nih.gov; collinsca@
ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
[FR Doc. 2023–20420 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
performance, and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Jkt 259001
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
65181
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIHAI75N93023R00003:
Pre-clinical Models of Infectious Diseases—
Task Area B.
Date: October 20–23, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Annie Walker-Abbey,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70A,
Rockville, MD 20852, 240–627–3390,
aabbey@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20493 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Human Liver and
Human Liver Cells Research Resource.
Date: November 17, 2023.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
E:\FR\FM\21SEN1.SGM
21SEN1
]]>Agencies
[Federal Register Volume 88, Number 182 (Thursday, September 21, 2023)]
[Notices]
[Pages 65180-65181]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20438]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
[[Page 65181]]
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Review of Institutional
Training Grants (T32) in Digestive Diseases and Nutrition.
Date: October 17, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, NIDDK, Democracy II, Suite
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Tori Stone, Ph.D., Scientific Review Officer,
NIDDK/Scientific Review Branch, National Institutes of Health, 6707
Democracy Blvd., Bethesda, MD 20892, (301) 827-0994,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: September 15, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20438 Filed 9-20-23; 8:45 am]
BILLING CODE 4140-01-P
